Proxy Results Form 8 K

Item 5.07 Submission of Matters to a Vote of Security Holders.

On November 14, 2024, Oruka Therapeutics, Inc. (the "Company") held its Special Meeting of Stockholders (the "Special Meeting"). Set forth below is a brief description of each matter considered and voted upon at the Special Meeting, together with the final tally of the number of votes cast for or against, as well as the number of abstentions and broker non-votes as to each such matter. A more complete description of each matter is set forth in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on October 18, 2024.

Proposal 1: Approval of Conversion of Series A Preferred Stock to Common Stock

The Company's stockholders approved the issuance of shares of the Company's common stock upon conversion of the Company's Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share, issued in September 2024. The tabulation of votes on this matter was as follows:

	Shares voted for:	30,598,476
	Shares voted against:	6,026
	Shares abstaining	1,089

There were no broker non-votes for this proposal.

Proposal 2: Approval of an Adjournment of the Special Meeting, if Necessary or Appropriate, to Solicit Additional Proxies

The Company's stockholders approved an adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies. The tabulation of votes on this matter was as follows:

	Shares voted for:	29,294,720
	Shares voted against:	1,309,805
	Shares abstaining	1,066

There were no broker non-votes for this proposal.

Public link

Please use the above public link if you want to share this noodl on another website.